Primo Nery Lara, Jr.

Clinical/Research Interests
Dr. Lara's clinical interests include genitourinary malignancies, lung cancer and clinical trials. His research focuses on developmental therapeutics and novel treatment approaches to cancer.

Title
Professor, Associate Director of Translational Research, Cancer Center, Co-Leader of the Cancer Therapeutics Program, Cancer Center

Specialty
Hematology and Oncology, Cancer, Internal Medicine

Center/Program Affiliation
UC Davis Comprehensive Cancer Center

Address
UC Davis Comprehensive Cancer Center, 4501 X St. 3016 Sacramento, CA 95817

Phone
916-734-5959

Education
University of the Philippines College of Medicine, Manila, Philippines, M.D., 1992
University of the Philippines College of Science, Diliman, Philippines, B.S., 1987

Internships
Rush Presbyterian-St Luke's Medical Center, Chicago, Illinois, 1993-1994 Internal Medicine
University of the Philippines-Philippine General Hospital, Manila, , 1991-1992 Internal Medicine

Residency
Rush Presbyterian-St. Luke's Medical Center, Chicago , Illinois, 1994-1996, Internal Medicine

Fellowships
UC Davis Medical Center, Sacramento, California, 1999, Hematology/Oncology

Board Certifications
American Board of Internal Medicine, 1996

Professional Memberships
American Society of Clinical Oncology
California Cancer Consortium
Internantional Association for the Study of Lung Cancer
Southwest Oncology Group

Honors and Awards
Paul Calabresi Career Development Award for Clinical Oncology, National Institutes of Health/National Cancer Institute, 2011-2016
NIH RO 1 Award: Markers of bone metabolism in prostate cancer, 2009-2011
National Institutes of Health (NIH)-R21 Award: Overcoming Barriers to Cancer Clinical Trials, 2003-2005
National Institutes of Health/National Cancer Institute (NIH/NCI) Translational Research Initiative Award, 2003-2004
University of California Cancer Research Coordinating Council Award, 2002-2003
Hope Foundation Translational Research Award, 2002-2003
Clinical Research Training Award, American Cancer Society, 2000-2005

UCDAVIS
HEALTH SYSTEM

Primo Nery Lara, Jr.

Christine Landgraf Memorial Award for Cancer Research, 1999
Most outstanding graduate of the Institute of Biology, College of Science, University of the Philippines, 1987
Magna cum laude, BS Biology, Institute of Biology, College of Science, University of the Philippines, 1987

Select Recent Publications

Lara PN Jr, Longmate J, Reckamp K, Gitlitz B, Argiris A, Ramalingam S, Belani CP, Mack PC, Lau DH, Koczywas M, Wright JJ, Shepherd FA, Leighl N, Gandara DR. Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. Clin Lung Cancer. 2011 Jan;12(1):33-7.

Ramalingam SS, Davies AM, Longmate J, Edelman MJ, Lara PN Jr, Vokes EE, Villalona-Calero M, Gitlitz B, Reckamp K, Salgia R, Wright JJ, Belani CP, Gandara DR. Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). J Thorac Oncol. 2011 Oct;6(10):1741-5.

Holland WS, Tepper CG, Pietri JE, Chinn DC, Gandara DR, Mack PC, Lara PN Jr. Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy. Cancer Chemother Pharmacol. 2011 Jun 5.

Shek D, Longmate J, Quinn DI, Margolin KA, Twardowski P, Gandara DR, Frankel P, Pan CX, Lara PN Jr. A phase II trial of gefitinib and pegylated IFNa in previously treated renal cell carcinoma. Int J Clin Oncol. 2011 Oct;16(5):494-9. Epub 2011 Mar 23.

Chamie K, Kurzrock EA, Evans CP, Litwin MS, Koppie TM, Wootton-Gorges SL, Boone JM, Lara PN Jr, Devere White RW. Secondary malignancies among nonseminomatous germ cell tumor cancer survivors. Cancer. 2011 Sep 15;117(18):4219-30. doi: 10.1002/cncr.26038. Epub 2011 Mar 15.

Semrad TJ, Gandara DR, Lara PN Jr. Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience. Ther Adv Med Oncol. 2011 Mar;3(2):95-100.

Lara PN Jr, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, Albert I, Losonczy G, Reck M, Heo DS, Fan X, Fandi A, Scagliotti G. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced

Primo Nery Lara, Jr.

non-small-cell lung cancer. J Clin Oncol. 2011 Aug 1;29(22):2965-71. Epub 2011 Jun 27

Chen AM, Lara PN Jr. Medical oncology: Chemoradiotherapy for NSCLC-does a 'standard' exist? Nat Rev Clin Oncol. 2011 Jan;8(1):5-6. Epub 2010 Nov 23.

Gandara DR, Grimminger P, Mack PC, Lara PN Jr, Li T, Danenberg PV, Danenberg KD. Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer. J Thorac Oncol. 2010 Dec;5(12):1933-8.

Wang S, Zhang H, Malfatti M, de Vere White R, Lara PN Jr, Turteltaub K, Henderson P, Pan CX. Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells. Chem Res Toxicol. 2010 Nov 15;23(11):1653-5. Epub 2010 Oct 28.

© 2013 UC Regents

UCDAVIS
HEALTH SYSTEM